aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

Core Insights - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis [1][5] Company Performance - The topline results from the EFZO-FIT trial indicated that the primary goal of steroid reduction was not achieved, with placebo tapering outperforming the company's expectations [5] - aTyr previously claimed that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [4] Market Reaction - Following the disappointing trial results, the market reacted severely, leading to a significant drop in share price and numerous analyst downgrades [5] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into aTyr for potentially misleading investors regarding the Phase 2 data and the design of the Phase 3 trial [2][6] - The investigation is focused on the accuracy of aTyr's disclosures and the implications of the failed trial results on investor expectations [3][6]